Abstract
Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
Volume: 20 Issue: 7
Author(s): Pallavi Singh Chauhan, Meerambika Mishra, Bhupendra Koul, Mayank Sharma and Dhananjay Yadav*
Affiliation:
- Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541,South Korea
Keywords: Alzheimer's disease, dementia, impaired sleep, insomnia, cognitive impairment, sleep disturbance.
Abstract: Sleep disorders have been shown to increase the risk of dementia. This particular aspect may affect the cognition of the patient, leading to behavioral disorders and depression. In early symptomatic Alzheimer’s Disease (AD), Default Mode Network (DMN) disruption occurs and progresses along with the course of the disease. This review mainly focuses on the leading causes of AD along with management of conditions like insomnia, obstructive sleep apnea, night-time sleep duration, Circadian Rhythm Disorder (CRD), neuroendocrine alternation, and impaired sleep to prevent the use of drugs that can cause complications, especially falls or additional cognitive deficits. Moreover, this study highlights the identification of molecular mechanisms like the effect of impaired sleep on amyloid β (Aβ) and tau dynamics, impaired proteostasis, along with appropriate measures to treat few contributing factors that lead to insomnia in AD or Mild Cognitive Impairment (MCI).
Export Options
About this article
Cite this article as:
Chauhan Singh Pallavi , Mishra Meerambika , Koul Bhupendra , Sharma Mayank and Yadav Dhananjay *, Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance, CNS & Neurological Disorders - Drug Targets 2021; 20 (7) . https://dx.doi.org/10.2174/1871527320666210319111852
DOI https://dx.doi.org/10.2174/1871527320666210319111852 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic:Targeted Alpha Particle Therapy (Guest Editors: Ganesan Vaidyanathan and Roy Larsen)]
Current Radiopharmaceuticals Clinical Potential of Neuropeptide Y Receptor Ligands in the Treatment of Epilepsy
Current Topics in Medicinal Chemistry HIV-Tuberculous Meningitis Co-Infection: A Systematic Review and Meta-Analysis
Current Pharmaceutical Biotechnology Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects
Current Drug Delivery Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research Fullerenes: From Carbon to Nanomedicine
Mini-Reviews in Medicinal Chemistry Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Cytokine/Antibody Complexes: An Emerging Class of Immunostimulants
Current Pharmaceutical Design Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry Preface
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research